HALOZYME THERAPEUTICS, INC. - Common Stock (HALO)

Q3 2016 13F Holders as of 30 Sep 2016

Type / Class
Equity / Common Stock
Shares outstanding
123,650,000
Total 13F shares
106,009,210
Share change
+1,018,812
Total reported value
$1,279,976,335
Put/Call ratio
39%
Price per share
$12.08
Number of holders
161
Value change
+$17,256,778
Number of buys
71
Number of sells
73

Institutional Holders of HALOZYME THERAPEUTICS, INC. - Common Stock (HALO) as of Q3 2016

As of 30 Sep 2016, HALOZYME THERAPEUTICS, INC. - Common Stock (HALO) was held by 161 institutional shareholders that filed Form 13F with the SEC. Together, they reported ownership of 106,009,210 shares. The largest 10 holders included Third Security, LLC, IRIDIAN ASSET MANAGEMENT LLC/CT, VANGUARD GROUP INC, FMR LLC, First Eagle Investment Management, LLC, BB BIOTECH AG, BlackRock Fund Advisors, STATE STREET CORP, BlackRock Institutional Trust Company, N.A., and JPMORGAN CHASE & CO. This page lists 161 institutional shareholders reporting positions in this security for the Q3 2016 filing period.
Investor Option Weight % Change % Value $ * Price Shares Share Change Activity Report Period
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.